These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1122 related articles for article (PubMed ID: 26699405)

  • 1. A visceral adiposity index-related dietary pattern and the cardiometabolic profiles in women with polycystic ovary syndrome.
    Ehsani B; Moslehi N; Mirmiran P; Ramezani Tehrani F; Tahmasebinejad Z; Azizi F
    Clin Nutr; 2016 Oct; 35(5):1181-7. PubMed ID: 26699405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
    Durmus U; Duran C; Ecirli S
    J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between visceral adiposity index, hirsutism and cardiometabolic risk factors in women with polycystic ovarian syndrome: A cross-sectional study.
    Fonseka S; Subhani B; Wijeyaratne CN; Gawarammana IB; Kalupahana NS; Ratnatunga N; Rosairo S; Vithane KP
    Ceylon Med J; 2019 Sep; 64(3):111-117. PubMed ID: 32120461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment.
    Amato MC; Guarnotta V; Forti D; Donatelli M; Dolcimascolo S; Giordano C
    Hum Reprod; 2013 Jul; 28(7):1919-28. PubMed ID: 23592224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Visceral Adiposity Index as Predictor of Metabolic Syndrome in Obese and Nonobese Women with Polycystic Ovary Syndrome.
    de Medeiros SF; de Medeiros MAS; Barbosa BB; Yamamoto MMW
    Metab Syndr Relat Disord; 2021 Feb; 19(1):18-25. PubMed ID: 32845813
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiometabolic risks in polycystic ovary syndrome: long-term population-based follow-up study.
    Behboudi-Gandevani S; Ramezani Tehrani F; Hosseinpanah F; Khalili D; Cheraghi L; Kazemijaliseh H; Azizi F
    Fertil Steril; 2018 Dec; 110(7):1377-1386. PubMed ID: 30503137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.
    Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome.
    Abruzzese GA; Cerrrone GE; Gamez JM; Graffigna MN; Belli S; Lioy G; Mormandi E; Otero P; Levalle OA; Motta AB
    Horm Metab Res; 2017 Jan; 49(1):23-29. PubMed ID: 27571188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
    Graff SK; Mário FM; Alves BC; Spritzer PM
    Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome.
    Androulakis II; Kandaraki E; Christakou C; Karachalios A; Marinakis E; Paterakis T; Diamanti-Kandarakis E
    Clin Endocrinol (Oxf); 2014 Sep; 81(3):426-31. PubMed ID: 24601936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study.
    Ramezani Tehrani F; Minooee S; Azizi F
    Eur J Endocrinol; 2014 Aug; 171(2):199-207. PubMed ID: 24816947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of a new anthropometric indicator - VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome.
    Brończyk-Puzoń A; Jagielski P; Kulik-Kupka K; Koszowska A; Nowak J; Zubelewicz-Szkodzińska B
    Adv Clin Exp Med; 2017 Aug; 26(5):825-828. PubMed ID: 29068579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LIPID ACCUMULATION PRODUCT, VISCERAL ADIPOSITY INDEX, AND CHINESE VISCERAL ADIPOSITY INDEX AS MARKERS OF CARDIOMETABOLIC RISK IN ADULT GROWTH HORMONE DEFICIENCY PATIENTS: A CROSS-SECTIONAL STUDY.
    Xie X; Li Q; Zhang L; Ren W
    Endocr Pract; 2018 Jan; 24(1):33-39. PubMed ID: 29144802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome].
    Roa Barrios M; Arata-Bellabarba G; Valeri L; Velázquez-Maldonado E
    Endocrinol Nutr; 2009 Feb; 56(2):59-65. PubMed ID: 19627713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.
    Anik Ilhan G; Yildizhan B; Pekin T
    Gynecol Endocrinol; 2019 Mar; 35(3):233-236. PubMed ID: 30303693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome.
    Rossi B; Sukalich S; Droz J; Griffin A; Cook S; Blumkin A; Guzick DS; Hoeger KM
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4780-6. PubMed ID: 18812482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimüllerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome.
    Feldman RA; O'Neill K; Butts SF; Dokras A
    Fertil Steril; 2017 Jan; 107(1):276-281. PubMed ID: 27842995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
    Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
    Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel predictor of metabolic risk in patients with polycystic ovary syndrome: could it be the visceral adiposity index?
    Apaydin M; Kazan ED; Beysel S; Sari A; Özgül E; Cengiz H; Demirci T; Yilmazer M
    Eur Rev Med Pharmacol Sci; 2022 Oct; 26(19):7182-7187. PubMed ID: 36263527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome.
    Oh JY; Sung YA; Lee HJ
    Obesity (Silver Spring); 2013 Aug; 21(8):1690-4. PubMed ID: 23585246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.